Polyphagia as an accompanying symptom of various diseases - overview and treatment options
DOI:
https://doi.org/10.12775/JEHS.2025.79.57792Keywords
polyphagia, obesity, diabetes, insulinoma, Prader-Willi syndrome, frontotemporal dementia, binge eating disorder, Grave’s disease, pharmacotherapy of obesityAbstract
Introduction and purpose
Polyphagia is a rare symptom described as an excessive food intake due to an abnormally strong and persistent sensation of hunger or desire to eat. Diseases that can lead to polyphagia are numerous and include several medical specialties, such as endocrinology, neurology and psychiatry. Polyphagia leads to overweight and severe obesity, reduces quality of life, has a negative impact on the patient’s mental health and eventually causes premature death. Therefore identifying and addressing the root cause of polyphagia is crucial for effective management and treatment. This article aims to explore the most common causes, the latest research and potentials in the treatment of polyphagia.
References
1. Human Phenotype Ontology – Polyphagia [Internet]. https://hpo.jax.org/browse/term/HP:0002591. Accessed 05.01.2025
2. Prevention and treatment of obesity has outgrown the system [transcript of press conference]. The Supreme Audit Office, [Internet], 2024. https://www.nik.gov.pl/aktualnosci/coraz-wiecej-osob-z-choroba-otylosciowa-coraz-dluzsze-kolejki.html. Accessed 05.01.2025. Polish.
3. Nutrition, Physical Activity & Obesity (NAO), Office for Prevention & Control of NCDs (MOS). WHO European Regional Obesity Report 2022 [Internet], 2022. https://www.who.int/europe/publications/i/item/9789289057738. Accessed 05.01.2025.
4. World Health Organization. Obesity and overweight [Internet], 2024. https://www.who.int/en/news-room/fact-sheets/detail/obesity-and-overweight. Accessed 05.01.2025
5. World Health Organization. New WHO Report: Europe can reverse its obesity “epidemic’’ [Internet], 2022. https://www.who.int/europe/news-room/03-05-2022-new-who-report--europe-can-reverse-its-obesity--epidemic. Accessed 05.01.2025
6. World Health Organization. Indicator Metadata Registry Details – Obesity [Internet]. https://www.who.int/data/gho/indicator-metadata-registry/imr-details/3420. Accessed 05.01.2025
7. Chong B, Jayabaskaran J, Kong G, et al. Trends and predictions of malnutrition and obesity in 204 countries and territories: an analysis of the Global Burden of Disease Study 2019. EClinicalMedicine 2023;57:101850.
8. Morton GJ, Schwartz MW. The NPY/AgRP neuron and energy homeostasis. Int J Obes Relat Metab Disord. 2001 Dec;25 Suppl 5:S56-62. doi: 10.1038/sj.ijo.0801915. PMID: 11840217.
9. Lee J, Raycraft L, Johnson AW. The dynamic regulation of appetitive behavior through lateral hypothalamic orexin and melanin concentrating hormone expressing cells. Physiol Behav. 2021 Feb 1;229:113234. doi: 10.1016/j.physbeh.2020.113234. Epub 2020 Oct 29. PMID: 33130035; PMCID: PMC8041470.
10. Singh M. Epigenetics in Hyperphagia. In: Patel V, Preedy V (ed.). Hanbook of Nutrition, Diet, and Epigenetics [Internet]. Cham: Springer International Publishing, 2017:1-19. https://doi.org/10.1007/978-3-319-31143-2_78-1. Accessed 05.01.2025
11. Arafa. N, Hassan MM, Atef S, et al. Clinical characteristics and precipitating factor(s) associated with diabetic ketoacidosis presentation in children with newly diagnosed diabetes. Clin Diabetol 2020;9(5)286-92.
12. Hong SH, Choi KM. Gut hormones and appetite regulation. Curr Opin Endocrinol Diabetes Obes. 2024 Jun 1;31(3):115-121. doi: 10.1097/MED.0000000000000859. Epub 2024 Mar 21. PMID: 38511400.
13. Devi KBL, Meitei KT, Singh SJ. Prevalence of Type 2 Diabetes and its Signs and Symptoms Among the Meiteis of Manipur, India. J Anthropol Surv India 2023;72(1):59-70.
14. Ishii S, Kamegai J, Tamura H, Shimizu T, Sugihara H, Oikawa S. Triiodothyronine (T3) stimulates food intake via enhanced hypothalamic AMP-activated kinase activity. Regul Pept. 2008 Nov 29;151(1-3):164-9. doi: 10.1016/j.regpep.2008.07.007. Epub 2008 Jul 29. PMID: 18708095.
15. Giel KE, Bulik CM, Fernandez-Aranda F, Hay P, Keski-Rahkonen A, Schag K, Schmidt U, Zipfel S. Binge eating disorder. Nat Rev Dis Primers. 2022 Mar 17;8(1):16. doi: 10.1038/s41572-022-00344-y. PMID: 35301358; PMCID: PMC9793802.
16. Nagata JM, Smith-Russack Z, Paul A, et al. The social epidemiology of binge-eating disorder and behaviors in early adolescents. J Eat Disord 2023;11(1):182
17. McCuen-Wurst C, Ruggieri M, Allison KC. Disordered eating and obesity: associations between binge-eating disorder, night-eating syndrome, and weight-related comorbidities. Ann N Y Acad Sci. 2018 Jan;1411(1):96-105. doi: 10.1111/nyas.13467. Epub 2017 Oct 16. PMID: 29044551; PMCID: PMC5788730.
18. Hofland J, Refardt JC, Feelders RA, Christ E, de Herder WW. Approach to the Patient: Insulinoma. J Clin Endocrinol Metab. 2024 Mar 15;109(4):1109-1118. doi: 10.1210/clinem/dgad641. PMID: 37925662; PMCID: PMC10940262.
19. Cai XJ, Evans ML, Lister CA, et al. Hypoglycemia activates orexin neurons and selectively increases hypothalamic orexin-B levels: responses inhibited by feeding and possibly mediated by the nucleus of the solitary tract. Diabetes 2001;50(1):105-12.
20. Piguet O, Petersén A, Yin Ka Lam B, Gabery S, Murphy K, Hodges JR, Halliday GM. Eating and hypothalamus changes in behavioral-variant frontotemporal dementia. Ann Neurol. 2011 Feb;69(2):312-9. doi: 10.1002/ana.22244. Epub 2010 Nov 12. PMID: 21387376; PMCID: PMC3084499.
21. Ahmed RM, Latheef S, Bartley L, Irish M, Halliday GM, Kiernan MC, Hodges JR, Piguet O. Eating behavior in frontotemporal dementia: Peripheral hormones vs hypothalamic pathology. Neurology. 2015 Oct 13;85(15):1310-7. doi: 10.1212/WNL.0000000000002018. Epub 2015 Sep 16. PMID: 26377252; PMCID: PMC4617167.
22. Butler MG, Miller JL, Forster JL. Prader-Willi Syndrome - Clinical Genetics, Diagnosis and Treatment Approaches: An Update. Curr Pediatr Rev. 2019;15(4):207-244. doi: 10.2174/1573396315666190716120925. PMID: 31333129; PMCID: PMC7040524.
23. Muscogiuri G, Barrea L, Faggiano F, Maiorino MI, Parrillo M, Pugliese G, Ruggeri RM, Scarano E, Savastano S, Colao A; RESTARE. Obesity in Prader-Willi syndrome: physiopathological mechanisms, nutritional and pharmacological approaches. J Endocrinol Invest. 2021 Oct;44(10):2057-2070. doi: 10.1007/s40618-021-01574-9. Epub 2021 Apr 23. PMID: 33891302; PMCID: PMC8421305.
24. Popoviciu MS, Păduraru L, Yahya G, Metwally K, Cavalu S. Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials. Int J Mol Sci. 2023 Jun 21;24(13):10449. doi: 10.3390/ijms241310449. PMID: 37445623; PMCID: PMC10341852.
25. Shah M, Vella A, Effects of GLP-1 on appetite and weight. Rev Endocr Metab Disord 2014;15(3):181-7.
26. Lazzaroni E, Ben Nasr M, Loretelli C, Pastore I, Plebani L, Lunati ME, Vallone L, Bolla AM, Rossi A, Montefusco L, Ippolito E, Berra C, D'Addio F, Zuccotti GV, Fiorina P. Anti-diabetic drugs and weight loss in patients with type 2 diabetes. Pharmacol Res. 2021 Sep;171:105782. doi: 10.1016/j.phrs.2021.105782. Epub 2021 Jul 22. PMID: 34302978.
27. Streetman DD, Khanderia U. Diagnosis and treatment of Graves disease. Ann Pharmacother. 2003 Jul-Aug;37(7-8):1100-9. doi: 10.1345/aph.1C299. PMID: 12841824.
28. Heo YA, Duggan ST. Lisdexamfetamine: A Review in Binge Eating Disorder. CNS Drugs. 2017 Nov;31(11):1015-1022. doi: 10.1007/s40263-017-0477-1. PMID: 29134566.
29. Peat CM, Brownley KA, Berkman ND, Bulik CM. Binge eating disorder: Evidence-based treatments. Curr Psychiatr. 2012 May;11(5):32-39. PMID: 26924948; PMCID: PMC4768866.
30. Brown E, Watkin D, Evans J, Yip V, Cuthbertson DJ. Multidisciplinary management of refractory insulinomas. Clin Endocrinol (Oxf). 2018 May;88(5):615-624. doi: 10.1111/cen.13528. Epub 2018 Mar 2. PMID: 29205458.
31. Kob M, Valzolgher L. Eating disorders in dementia: Binge Eating in frontotemporal dementia (FTD). IPA Bull 2023;40:12.
32. Alsaif M, Elliot SA, MacKenzie ML, Prado CM, Field CJ, Haqq AM. Energy Metabolism Profile in Individuals with Prader-Willi Syndrome and Implications for Clinical Management: A Systematic Review. Adv Nutr. 2017 Nov 15;8(6):905-915. doi: 10.3945/an.117.016253. PMID: 29141973; PMCID: PMC5682993.
33. Krasińska A, Skowrońska B. [Prader-Willi Syndrome - nutritional management in children, adolescents and adults]. Pediatr Endocrinol Diabetes Metab. 2017;23(2):101-106. Polish. doi: 10.18544/PEDM-23.02.0080. PMID: 29073293.
34. Miller JL, Tan M. Dietary Management for Adolescents with Prader-Willi Syndrome. Adolesc Health Med Ther. 2020 Aug 25;11:113-118. doi: 10.2147/AHMT.S214893. PMID: 32922110; PMCID: PMC7457755.
35. Barrea L, Vetrani C, Fintini D, de Alteriis G, Panfili FM, Bocchini S, Verde L, Colao A, Savastano S, Muscogiuri G. Prader-Willi Syndrome in Adults: An Update On Nutritional Treatment and Pharmacological Approach. Curr Obes Rep. 2022 Dec;11(4):263-276. doi: 10.1007/s13679-022-00478-w. Epub 2022 Sep 5. PMID: 36063285; PMCID: PMC9729321.
36. Miller JL, Linville TD, Dykens EM. Effects of metformin in children and adolescents with Prader-Willi syndrome and early-onset morbid obesity: a pilot study. J Pediatr Endocrinol Metab. 2014 Jan;27(1-2):23-9. doi: 10.1515/jpem-2013-0116. PMID: 23893676; PMCID: PMC3864175.
37. Consoli A, Çabal Berthoumieu S, Raffin M, Thuilleaux D, Poitou C, Coupaye M, Pinto G, Lebbah S, Zahr N, Tauber M, Cohen D, Bonnot O. Effect of topiramate on eating behaviours in Prader-Willi syndrome: TOPRADER double-blind randomised placebo-controlled study. Transl Psychiatry. 2019 Nov 4;9(1):274. doi: 10.1038/s41398-019-0597-0. PMID: 31685813; PMCID: PMC6828670.
38. Wolfe G, Salehi V, Browne A, Riddle R, Hall E, Fam J, Tichansky D, Myers S. Metabolic and bariatric surgery for obesity in Prader Willi syndrome: systematic review and meta-analysis. Surg Obes Relat Dis. 2023 Aug;19(8):907-915. doi: 10.1016/j.soard.2023.01.017. Epub 2023 Feb 1. PMID: 36872159.
39. Tripodi M, Casertano A, Peluso M, et al. Prader-Willi Syndrome: Role of Bariatric Surgery in Two Adolescents with Obesity. Obes Surg. 2020;30(11):4602–4604. doi: 10.1007/s11695-020-04708-9.
40. Franco RR, Fonoff ET, Alvarenga PG, Alho EJL, Lopes AC, Hoexter MQ, Batistuzzo MC, Paiva RR, Taub A, Shavitt RG, Miguel EC, Teixeira MJ, Damiani D, Hamani C. Assessment of Safety and Outcome of Lateral Hypothalamic Deep Brain Stimulation for Obesity in a Small Series of Patients With Prader-Willi Syndrome. JAMA Netw Open. 2018 Nov 2;1(7):e185275. doi: 10.1001/jamanetworkopen.2018.5275. PMID: 30646396; PMCID: PMC6324383.
41. Crinò A, Fintini D, Bocchini S, Grugni G. Obesity management in Prader-Willi syndrome: current perspectives. Diabetes Metab Syndr Obes. 2018 Oct 4;11:579-593. doi: 10.2147/DMSO.S141352. PMID: 30323638; PMCID: PMC6175547. Butler MG. Management of obesity in Prader-Willi syndrome. Nat Clin Pract Endocrinol Metab. 2006;2(11):592–593. doi: 10.1038/ncpendmet0320.
42. Tan Q, Orsso CE, Deehan EC, et al. Current and emerging therapies for managing hyperphagia and obesity in Prader-Willi syndrome: A narrative review. Obes Rev. 2020;21(5):e12992. doi: 10.1111/obr.12992.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Monika Kułaga, Anna Kasprzak, Monika Grzybek, Diana Mazur-Lesińska, Barbara Szostak, Sylwia Wielgosz-Biała, Krzysztof Tyszkiewicz, Borys Łozowski, Małgorzata Kasprzak, Barbara Wilczyńska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 162
Number of citations: 0
